Benjamin Edwards Inc. Sells 3,735 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Benjamin Edwards Inc. lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 16.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,362 shares of the biopharmaceutical company’s stock after selling 3,735 shares during the quarter. Benjamin Edwards Inc.’s holdings in Gilead Sciences were worth $1,487,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the company. Commonwealth Equity Services LLC boosted its position in Gilead Sciences by 12.9% during the fourth quarter. Commonwealth Equity Services LLC now owns 372,452 shares of the biopharmaceutical company’s stock valued at $30,172,000 after acquiring an additional 42,554 shares during the last quarter. Robertson Stephens Wealth Management LLC boosted its position in shares of Gilead Sciences by 32.4% during the 4th quarter. Robertson Stephens Wealth Management LLC now owns 5,349 shares of the biopharmaceutical company’s stock worth $433,000 after purchasing an additional 1,310 shares in the last quarter. McIlrath & Eck LLC boosted its position in shares of Gilead Sciences by 67.2% during the 4th quarter. McIlrath & Eck LLC now owns 550 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 221 shares in the last quarter. First Trust Direct Indexing L.P. boosted its position in shares of Gilead Sciences by 23.0% during the 4th quarter. First Trust Direct Indexing L.P. now owns 30,157 shares of the biopharmaceutical company’s stock worth $2,443,000 after purchasing an additional 5,648 shares in the last quarter. Finally, Searle & CO. bought a new position in shares of Gilead Sciences during the 4th quarter worth about $328,000. Institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now owns 96,304 shares in the company, valued at approximately $7,026,339.84. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.16% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

GILD has been the topic of a number of research analyst reports. Cantor Fitzgerald cut their price objective on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 7th. StockNews.com raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, April 27th. HSBC raised shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective on the stock in a research report on Wednesday, April 24th. UBS Group cut their price objective on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Finally, Truist Financial cut shares of Gilead Sciences from a “buy” rating to a “hold” rating and dropped their price target for the company from $91.00 to $82.00 in a research report on Thursday, February 22nd. Eleven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $83.69.

Gilead Sciences Stock Down 0.4 %

NASDAQ:GILD traded down $0.25 on Thursday, hitting $65.26. The stock had a trading volume of 2,420,602 shares, compared to its average volume of 7,417,535. The company has a debt-to-equity ratio of 1.08, a quick ratio of 0.72 and a current ratio of 0.98. The stock has a market cap of $81.25 billion, a P/E ratio of 180.94, a price-to-earnings-growth ratio of 1.31 and a beta of 0.22. Gilead Sciences, Inc. has a 1 year low of $64.63 and a 1 year high of $87.86. The firm’s fifty day simple moving average is $70.87 and its two-hundred day simple moving average is $76.01.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating the consensus estimate of ($1.49) by $0.17. The firm had revenue of $6.69 billion during the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter last year, the business posted $1.37 EPS. Analysts predict that Gilead Sciences, Inc. will post 3.74 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be paid a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.72%. Gilead Sciences’s payout ratio is currently 855.56%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.